Cambridge Cog Regulatory News (COG)

4 March 2015

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

US office opened

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, announces the opening of a US office in Salt Lake City to meet the growing demand from both existing and new North American customers. This is a central development for the Company and highlights the Company's strategy to target this market.

The US office will be headed by former Baxter and Myriad executive Bill Rusconi and will support the continuing use of Cantab as the leading cognitive assessments in both pharmaceutical clinical trials and academic research but also increase the global reach of the Company's emerging healthcare technology division.

The cloud-based Cantab Connect range is already used extensively in central nervous system (CNS) drug trials, where the iPad based products have gained widespread acceptance for their ability to deliver rapid, accurate and reproducible clinical measures of cognitive function across multiple sites. However, a growing awareness of the need to assess cognitive performance is contributing to the increased adoption of Cantab technology in pharmaceutical, academic and healthcare sectors.

Commenting on the announcement, Dr Nick Kerton, CEO of Cambridge Cognition said: "The establishment of a US office, with a team providing business development, customer support and cognitive science experience and expertise, is a natural move for Cambridge Cognition. Having a strong US presence will not only enable us to strengthen our leadership in the pharmaceutical clinical trials market, but also to invest in the education and conversion of customers in internationally renowned centres where academic research, clinical development and healthcare diagnostics come together."

Enquiries:

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.